Printer Friendly

PATRICIA F. DIMOND, PH.D., JOINS TSI CORPORATION AS DIRECTOR OF CORPORATE COMMUNICATIONS

 WORCESTER, Mass., Jan. 19 /PRNewswire/ -- TSI Corporation (NASDAQ: TSIN) announced the appointment of Patricia F. Dimond, Ph.D., as director of corporate communications, with responsibility for the company's investor relations, and science and marketing communications programs.
 "Patricia brings over 15 years of communications management experience as well as an extensive business and technical background in biotechnology," said Jim Sherblom, chairman and CEO of TSI. "She is a great addition to TSI and we expect she will enhance our communications to the investment community and to our customers."
 Dr. Dimond was most recently manager of science and marketing communications and technology assessment at Becton Dickinson/Collaborative Biomedical Products. She was formerly editor of BioTechniques and Peptide Research, a senior science editor for Nature Publishing, and a founding editor of Drug Therapy, a pharmaceutical journal for physicians. She currently serves as a contributing editor for Genetic Engineering News. Dr. Dimond also held the position of director of business development at American BioTechnologies, a producer of recombinant AIDS-virus associated proteins, in Cambridge, Mass., with responsibility for identifying enabling technologies for the company, and developing its first customer base.
 Dr. Dimond holds a Ph.D. degree in biochemistry and cell biology from the Catholic University of America, a M.Sc. in physiology and biophysics from Georgetown University, and an M.A. in science communications from Boston University.
 TSI is a life sciences company offering in vitro and in vivo preclinical and toxicology testing services, human clinical testing services, and diagnostic intermediate products. TSI is developing advanced toxicology tests and disease models based on genetic engineering and transgenic techniques to improve the efficiency of the pharmaceutical/clinical development process.
 -0- 1/19/93
 /CONTACT: Patricia F. Dimond, Ph.D., director, corporate communications of TSI Corporation, 508-755-0550; or Robert Gottlieb, senior vice president of Feinstein Partners, Inc., 617-577-8110 for TSI/
 (TSIN)


CO: TSI Corporation ST: Massachusetts IN: MTC SU: PER

DD -- NE006 -- 6152 01/19/93 08:59 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 19, 1993
Words:323
Previous Article:NUTRAMAX REPORTS RECORD FIRST QUARTER SALES AND EARNINGS
Next Article:MEDIA LOGIC THIRD QUARTER SALES AND EARNINGS SET NEW RECORDS
Topics:


Related Articles
TSI CORPORATION REPORTS SIX-MONTH AND SECOND QUARTER RESULTS
TSI CORPORATION ANNOUNCES MANAGEMENT APPOINTMENTS
TSI CORPORATION FORECASTS THIRD QUARTER RESULTS AND INTENSIFIES FISCAL 1993 COST REDUCTION PROGRAM
TSI CORPORATION REPORTS MANAGEMENT CHANGES; FORECASTS ANTICIPATED THIRD QUARTER LOSS
TSI CORPORATION REPORTS PROGRESS TOWARD SMALL ANIMAL MODEL FOR AIDS
TSI CORPORATION REPORTS NINE-MONTH AND THIRD QUARTER RESULTS
Aventis Pharma and Coley Pharmaceutical Group Expand Partnership; -- Expansion Of Asthma and Allergic Rhinitis Collaboration Triggers $2M Milestone...
Coley Pharmaceutical Group Initiates Phase I Clinical Trial of CpG 7909 In Combination With Rituxan (R) to Treat Non-Hodgkin's Lymphoma.
Coley Pharmaceutical Group Strengthens Management Team and Expands Board of Directors.
Coley Pharmaceutical Group Receives Ninth U.S. Patent; -- Patent covers use of CpG oligos in combination with adjuvants to enhance immune responses...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters